Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16308154 | 0.91 | PIK3CB (0.41) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL17529201 | 0.89 | PIK3CB (0.40) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15029823 | 0.88 | PIK3CB (0.57) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15029959 | 0.88 | PIK3CB (0.46) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15029918 | 0.87 | PIK3CB (0.45) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL17529138 | 0.85 | PIK3CB (0.45) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10125552 | 0.81 | PIK3CB (0.54) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10125106 | 0.80 | PIK3CB (0.57) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10154227 | 0.80 | PIK3CB (0.59) | NAPEPLDPIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL10125553 | 0.79 | PIK3CB (0.52) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | IL2, NFATC1, ICOS | NAPEPLD 1283/4885PIK3CB 16/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.